Heron Therapeutics Inc vs Toyota Motor Corp — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Toyota Motor Corp trades at $189.07 (market cap $223.57B). The key difference: Toyota Motor Corp is far larger — about 3525.8× Heron Therapeutics Inc's market cap, and Toyota Motor Corp pays a 3.32% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TM | |
|---|---|---|
Market Cap | $63.41M | $223.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $248.29 |
52-Week Low | $0.33 | $166.50 |
Enterprise Value | $161.31M | $417.39B |
Dividend Yield | — | 3.32% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Toyota Motor (TM) trades at $190.09, up 1.39% with bullish technical signals and strong fundamentals. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $7.57 exceeding expectations by 62%. Valuation remains attractive with P/E of 8.48 and P/B of 0.95, while revenue growth continues at $48.04T for 2025. Technical indicators show bullish moving averages and support at $189.
Outlook remains positive given strong hybrid vehicle demand and raised earnings guidance, though risks include China sales weakness and recall-related costs. Analyst consensus leans cautious with 62.5% hold ratings despite no sell recommendations. The stock presents value opportunity with solid cash flow generation and market leadership position.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →